Liraglutide Exerts Weight Loss-Independent, GLP-1R-Dependent Effects
16 Jan 2024
Clinical Result
TUESDAY, Jan. 16, 2024 -- Use of the glucagon-like peptide 1 receptor (GLP-1R) agonist liraglutideglucagon-like peptide 1 receptor (GLP-1R) agonist liraglutide exerts weight loss-independent, GLP-1R-dependent effects on insulin sensitivity, according to a study published online Oct. 24 in Diabetes.
Mona Mashayekhi, M.D., Ph.D., from Vanderbilt University Medical Center in Nashville, Tennessee, and colleagues examined whether GLP-1R agonistsGLP-1R agonists exert weight loss-independent, GLP-1R-dependent effects that differ from those of increasing endogenous GLP-1. Individuals with obesity and prediabetes were randomly allocated to receive 14 weeks of the GLP-1R agonist liraglutideGLP-1R agonist liraglutide, a hypocaloric diet, or the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin.
The researchers found that weight loss occurred with liraglutide and diet but not sitagliptin. After two weeks, prior to weight loss, liraglutide improved insulin sensitivity measured by the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), Homeostatic Model Assessment 2 (HOMA2), and the Matsuda index. Reductions in fasting and postprandial glucose, insulin, C-peptide, and fasting glucagon levels were also seen with liraglutide. In contrast, improvements were seen in insulin sensitivity by HOMA-IR and HOMA2 but not Matsuda index with diet-induced weight loss. However, there was no reduction in glucose levels. Increases in endogenous GLP-1 and gastric inhibitory peptide (GIP) values were seen with sitagliptin with no alteration of insulin sensitivity or fasting glucose, and reductions were seen in postprandial glucose and glucagon. Sitagliptin increased GIP, with no alteration in weight.
"We were surprised to find that the GLP-1R agonistGLP-1R agonist liraglutide also has rapid effects on insulin sensitivity, independent from weight loss," Mashayekhi said in a statement. "Increasing the body's own endogenous GLP-1 through the use of the DPP-4 inhibitor sitagliptin does not achieve similar effects."
Two authors disclosed ties to industry. Novo Nordisk provided liraglutide and matching placebo for the study.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.